Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Insmed, with a price target of $212.00. Skor covers the Hea...

Morgan Stanley Keeps Their Buy Rating on Insmed (INSM)

In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on Insmed, with a price target of $207.00. According to TipRanks, D...

Guggenheim Reaffirms Their Buy Rating on Insmed (INSM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Parabilis Medicines, Inc. (PBLS) and Insmed (INSM) w...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zura Bio (ZURA), Insmed (INSM) and Harmony Bioscie...

Analysts Conflicted on These Healthcare Names: Zura Bio (ZURA), Insmed (INSM) and Harmony Biosciences Holdings (HRMY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Health Catalyst (HCAT) and Insmed (INSM). Health C...

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Insmed (INSM)

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Insmed today and set a price target of $192.00. According to TipRanks, Suvan...

Mizuho Securities Remains a Buy on Insmed (INSM)

In a report released on July 7, Leonid Timashev from RBC Capital maintained a Buy rating on Insmed, with a price target of $195.00. The company’s s...

Insmed (INSM) Receives a Buy from RBC Capital

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM), Biogen (BIIB) and Vertex Pharmaceutic...

Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Biogen (BIIB)

Healthcare remains one of the market’s most steady sectors this year, backed by biotech innovation and medical device strength. According to analys...

3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts

Analysts have been eager to weigh in on the Healthcare sector with new ratings on ACADIA Pharmaceuticals (ACAD) and Insmed (INSM). ACADIA Pharmaceu...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INSM	$104.73	-2.05%	1.90M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INSM	$104.73	-2.0%	1.90M
3
4
5
6

INSM

INSM

Get Insmed Incorporated Data in Excel

Get Insmed Incorporated Data in Excel